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Summary
Background.  —  The  operative  risk  of  cardiac  surgery  is  ascertained  preoperatively  on  the  basis
of scores  validated  in  multinational  studies.  However,  the  value  they  add  to  a  simple  bedside
clinical evaluation  (CE)  remains  controversial.
Abbreviations: ACEF, age-creatinine-ejection fraction; AVR, aortic valve replacement; CABG, coronary artery bypass graft; CE, clinical
evaluation; CI, conﬁdence interval; ES-add, additive EuroSCORE; ES-log, logistic EuroSCORE; LVEF, left ventricular ejection fraction; STS,
Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation.
∗ Corresponding author. Service de cardiologie, CHU Pontchaillou, 35033 Rennes cedex, France.
E-mail address: marcel.laurent@chu-rennes.fr (M. Laurent).
1875-2136/$ — see front matter © 2013 Elsevier Masson SAS. All rights reserved.
http://dx.doi.org/10.1016/j.acvd.2013.09.001
652  M.  Laurent  et  al.
Operative  mortality;
Operative  risk
assessment
Aims.  —  To  compare  operative  mortality  (deﬁned  as  death  from  all  causes  before  the  31st
postoperative  day)  predicted  by  CE  with  that  predicted  by  additive  and  logistic  EuroSCOREs,
EuroSCORE  II  and  Society  of  Thoracic  Surgeons  (STS),  Ambler  and  age-creatinine-ejection  frac-
tion (ACEF)  scores  in  patients  undergoing  aortic  valve  replacement  (AVR)  for  severe  aortic
stenosis.
Methods.  —  Overall,  314  consecutive  patients  were  included  who  underwent  AVR  between  Octo-
ber 2009  and  November  2011  (22%  with  coronary  artery  bypass  graft);  mean  age  73.4  ±  9.7  years
(29% aged  >  80  years).  Based  on  CE,  patients  were  divided  into  four  predeﬁned  groups  of  increas-
ing estimated  mortality  risk:  I ≤  3.9%;  II  4—6.9%;  III  7—9.9%;  IV  ≥  10%.  The  positive  and  negative
predictive  values  of  the  six  scores  and  CE  were  compared.
Results.  —  The  observed  overall  operative  mortality  was  5.7%.  The  distribution  of  the  four
predicted  mortality  groups  by  each  score  was  highly  variable.  The  positive  predictive  value,
calculated  for  the  64  patients  classiﬁed  at  highest  risk  by  CE  (groups  III  or  IV)  or  each  score,  was
17.2% for  EuroSCORE  II,  14.1%  for  CE  and  STS  scores,  10.9%  for  additive  and  logistic  EuroSCOREs,
10.6% for  ACEF  and  10.2%  for  Ambler.  The  positive  predictive  value  of  each  score  in  the  low-risk
groups (I  and  II)  ranged  from  2.8%  to  4.4%.
Conclusion.  —  A  simple  bedside  CE  appears  as  reliable  as  the  various  established  scores  for
predicting  operative  risk  in  patients  undergoing  surgical  aortic  valve  replacement.  The  devel-
opment and  validation  of  more  comprehensive  risk  stratiﬁcation  tools,  including  risk  factors
thus far  neglected,  seems  warranted.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Le  risque  opératoire  de  la  chirurgie  cardiaque  est  évalué  en  préopératoire  sur  la
base de  scores  internationaux  validés.  Néanmoins,  leur  valeur  ajoutée  par  rapport  à  l’évaluation
clinique simple  reste  controversée.
Objectifs.  —  Cette  étude  a  comparé  la  mortalité  opératoire  (déﬁnie  comme  le  décès  de  toute
cause avant  le  31e jour  postopératoire)  prédite  par  l’évaluation  clinique,  avec  celle  prédite  par
l’EuroSCORE  additif  et  logistique,  l’EuroSCORE  II,  le  score  de  la  Society  of  Thoracic  Surgeons
(STS), le  score  d’Ambler  et  le  score  ACEF  (âge-créatinine-fraction  d’éjection)  chez  des  patients
opérés d’un  remplacement  valvulaire  aortique  pour  sténose  aortique  serrée.
Méthodes.  — Ont  été  inclus  314  patients  consécutifs  (73,4  ±  9,7  ans  d’âge,  dont  29  %  de  plus  de
80 ans)  ayant  subi  un  remplacement  valvulaire  aortique  entre  octobre  2009  et  novembre  2011,
associé à  un  ou  des  pontages  coronaires  pour  22  %  d’entre  eux.  En  fonction  de  l’évaluation
clinique, les  patients  étaient  répartis  en  4  groupes  prédéﬁnis  de  risque  opératoire  croissant:
I ≤  3,9  %  ;  II  4—6,9  %  ;  III  7—9,9  %  ;  IV  ≥  10  %.  Les  valeurs  prédictives  positive  et  négative  des
6 scores  et  de  l’évaluation  clinique  ont  été  comparées.
Résultats.  — La  mortalité  opératoire  observée  était  de  5,7  %.  La  répartition  selon  les  4  groupes
de mortalité  prédite  était  hautement  variable  d’un  score  à  l’autre.  La  valeur  prédictive  positive
calculée pour  les  64  patients  classés  les  plus  à  risque  par  l’EC  (groupes  III  et  IV)  ou  par  chacun
des scores,  était  de  17,2  %  pour  l’EuroSCORE  II,  14,1  %  pour  l’évaluation  clinique  et  le  score
STS, 10,9  %  pour  l’EuroSCORE  additif  et  logistique,  10,6  %  pour  l’ACEF  et  10,2  %  pour  l’Ambler.
La valeur  prédictive  positive  de  chaque  score  dans  le  groupe  bas  risque  (I  et  II)  se  situait  entre
2,8 et  4,4  %.
Conclusion.  —  Une  évaluation  clinique  simple  semble  aussi  ﬁable  que  les  scores  dans  la  pré-
diction du  risque  opératoire  du  remplacement  valvulaire  aortique.  Le  développement  et  la
validation  d’outils  plus  élaborés  d’estimation  du  risque,  incluant  des  facteurs  jusque  là  négligés,
semblent mérités.
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ackground
ortic  stenosis  is  the  most  prevalent  and  the  most  often
perated  on  valvular  heart  disease  in  Europe  and  North
merica.  The  5-year  survival  of  patients  who  present  with
evere  non-operated  aortic  stenosis  is  approximately  30%,
hile  the  current  operative  mortality  associated  with  aor-
ic  valve  replacement  (AVR)  is  <  5%,  although  it  is  higher
m
p
os  droits  réservés.
n  the  elderly  and  in  patients  presenting  with  major  co-
orbidity  [1—3]. Furthermore,  transcatheter  aortic  valve
mplantation  (TAVI)  may  now  be  an  option  for  patients  who,
ntil  recently,  were  considered  inoperable.  Therefore,  the
stimation  of  operative  risk  is  at  the  centre  of  the  decision-
aking  process.  According  to  the  European  professional
ractice  guidelines  ‘‘the  risk  assessment  should  mostly  rely
n  the  clinical  judgement  of  the  ‘heart  team’  in  addition  to
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7Operative  risk  in  severe  aortic  valve  stenosis  
the  combination  of  scores’’  [2].  Nevertheless,  to  the  best  of
our  knowledge,  the  performance  of  a  simple  bedside  clinical
evaluation  (CE)  has  never  been  compared  with  the  scores.
While  their  merits  have  been  highlighted,  the  limitations  of
the  existing  scoring  systems  have  also  been  emphasized,  par-
ticularly  the  differences  among  the  variables  used  and  their
respective  weights  —  a  source  of  major  discordance  among
the  various  models  [4—6].  The  aim  of  this  ﬁrst  prospective
study  was  to  compare  the  predictive  value  of  a  standard-
ized  ‘‘bedside’’  preoperative  CE,  with  that  of  a  preoperative
estimate  based  on  the  main  risk  scores,  in  patients  who
underwent  valve  replacement  for  severe  aortic  stenosis.
Methods
Between  September  2009  and  November  2011,  consecu-
tive  patients  who  underwent  preoperative  evaluations  of
severe  aortic  stenosis  in  the  Department  of  Cardiology  of
Rennes  University  Hospital  were  prospectively  included  in
this  analysis,  before  being  referred  to  the  Department  of
Cardiothoracic  Surgery  of  the  same  hospital,  to  undergo
mechanical  or  bioprosthetic  AVR,  with  or  without  coronary
artery  bypass  graft  (CABG).  The  echocardiographical  crite-
ria  used  to  diagnose  severe  aortic  stenosis  were:  a  valve
area  <  1  cm2;  a  mean  transvalvular  gradient  >  40  mmHg;  or
a  jet  velocity  >  4  m/s,  as  deﬁned  by  the  2008  guidelines  of
the  American  College  of  Cardiology/American  Heart  Associ-
ation  [7].  Patients  who  underwent  additional  cardiovascular
operative  procedures  other  than  CABG  were  excluded  from
the  study.  The  study  protocol  was  approved  by  our  institu-
tional  review  board  and  the  patients  granted  their  informed
consent  to  participate.
The  CE  was  based  on  a  consensus  reached  among  car-
diologists  who  examined  the  patient  and  ordered  the
preoperative  workup.  It  consisted  of  classifying  patients
on  a  four-grade  scale  of  estimated  mortality  risk:  grade
I  (0—3.9%),  grade  II  (4—6.9%),  grade  III  (7—9.9%),  or
grade  IV  (≥10%),  based  on  the  results  of  all  diagnostic
investigations,  which  usually  comprised  history,  physical
examination,  echocardiogram,  coronary  angiograms,  respi-
ratory  functional  exploration  with  spirometry,  complete
blood  count,  haemostasis  and  renal  function  tests  with  cre-
atinine  clearance  and  status  of  peripheral  arterial  vessels
(namely  ultrasonography  of  the  carotid  and  vertebral  arter-
ies).  Final  grading  reﬂected  the  opinion  of  at  least  three
to  four  physicians.  Fifteen  experienced  cardiologists  in  two
teams  (age  range  30—61  years)  participated  in  the  CE  pro-
cess  and  grading.  The  reproducibility  of  CE  was  tested  with
six  surgeons  and  eight  anaesthesiologists.  All  physicians  who
participated  in  CE  were  unaware  of  the  results  of  calcu-
lated  scores.  The  interobserver  reproducibility  of  CE  grading
was  tested  in  a  sample  of  84  patients  who  underwent  dupli-
cate  CE  by  the  surgeon  and  another  sample  of  68  patients
who  underwent  duplicate  CE  by  the  anaesthesiologist,  both
unaware  of  the  results  of  the  ﬁrst  CE  by  the  cardiologists.
Furthermore,  we  calculated  independently  and  veriﬁed  sys-
tematically  six  operative  risk  scores:  additive  EuroSCORE
(ES-add),  logistic  EuroSCORE  (ES-log),  EuroSCORE  II  (ES  II),
Society  of  Thoracic  Surgeons  (STS)  score,  Ambler  score,  and
age-creatinine-ejection  fraction  (ACEF)  score.  ES  II  and  ACEF
were  calculated  retrospectively  at  the  end  of  the  study.
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EuroSCORE,  the  most  often  used  score,  is  based  on  17
ariables,  with  either  a  simple  additive  mode  (ES-add)  or  a
omputer-based  algorithm  (ES-log).  This  score  [8]  was  devel-
ped  in  1995,  from  a  database  of  14,000  patients.  ES  II,
ts  updated  version,  was  published  in  2011  [9].  The  Soci-
ty  of  Thoracic  Surgeons  (STS)  score  includes  approximately
0  variables  that  are  regularly  updated  [10]. The  Ambler
core  was  designed  for  risk  stratiﬁcation  in  valve  surgery
y  British  investigators  in  2005,  based  on  16,000  patients;
t  can  be  calculated  rapidly  on  the  basis  of  13  variables
11]. All  of  these  scores  are  accessible  via  a  website.  The
ore  recent  ACEF  score,  based  on  age,  serum  creatinine
oncentration  and  left  ventricular  ejection  fraction  (LVEF),
as  been  found,  in  some  studies,  to  be  superior  to  the  other
cores  [4].  The  various  components  of  the  different  scores
re  summarized  in  Table  1. The  Charlson-age  co-morbidity
ndex  [12]  (a  useful  complement  to  the  risk  scores  for  non-
ardiovascular  co-morbidity,  which  is  often  used  in  geriatric
edicine,  oncology  and  non-cardiac  surgery),  was  also  cal-
ulated,  although  it  was  not  included  in  all  between-scores
omparisons.
Operative  mortality  was  deﬁned  as  death  from  all  causes
ccurring  before  the  31st  postoperative  day,  based  on  a
eview  of  records,  postal  correspondence  or  telephone
ontact  with  the  patient,  the  cardiologist  or  the  family
hysician.  No  patient  was  lost  to  follow-up.
CE  grading  was  ﬁrst  compared  with  each  score  with
espect  to  the  four  previously  described  categories  of  esti-
ated  risk.  A  second  comparison  was  done  for  the  same
umber  of  patients  at  highest  risk  (n  =  64)  according  to
ach  scoring  method  or  CE  grading,  deﬁning  a  high-risk
roup  depending  on  the  score  or  method  chosen.  The  other
atients  deﬁned  the  low-risk  group.
tatistical analyses
ontinuous  variables,  expressed  as  means  ±  standard  devi-
tions,  were  compared  using  Student’s  t-test.  Qualitative
ariables,  expressed  as  counts  and  percentages,  were
ompared  using  the  chi2 test  or  Fisher’s  exact  test,  as  appro-
riate.  The  kappa  test  was  used  to  examine  the  agreement
etween  the  scores  and  CE;  a  value  of  1  indicated  100%
greement,  while  a  value  of  0  indicated  agreement  equiva-
ent  to  chance.  Receiver  operating  characteristic  analysis,
roducing  an  area  under  the  curve  with  95%  conﬁdence
ntervals  (CIs),  was  used  for  discrimination  of  the  predic-
ive  scores  of  30-day  mortality.  Risks  (and  95%  CIs)  were
alculated  to  compare  risk  groups.  A  P value  <  0.05  was  con-
idered  signiﬁcant.  The  analyses  were  performed  with  the
AS  software,  version  9.2  (SAS  Institute,  Cary,  NC,  USA).
esults
atients
 total  of  314  consecutive  patients  (mean  age
3.4  ±  9.7  years;  range  22—90  years)  were  included,  of
hom  91  (29%)  were  aged  >  80  years,  129  (41%)  were
omen  and  19  (6%)  were  asymptomatic.  The  baseline
haracteristics  of  the  sample  population  are  shown  in
able  2.  The  mean  aortic  valve  area  was  0.72  ±  0.16  cm2
654  M.  Laurent  et  al.
Table  1  Risk  score  variables.
STS  score  ES-add/log  ES  II  Ambler  ACEF
Patient  characteristics
Age  +  +  +  +  +
Sex  +  +  +  +
Height  +
Weight  +
Body  mass  index  +
Ethnicity  +
Co-morbid  conditions
Diabetes  +  +  (I)
Hypertension  +  +
Chronic  lung/pulmonary  disease  +  +  +
Extracardiac  arteriopathy  +  +  +
Peripheral  vascular  disease  +
Neurological  dysfunction  +  +
Cerebrovascular  accident  +
Serum  creatinine  +  +  +  +  +
Dialysis-dependent  renal  failure  +  +
Immunosuppressive  therapy +
Poor  mobility  +
Cardiac  history
NYHA  classiﬁcation  +  +
Unstable  angina  +  +
CCS  class  4  angina +
Recent  myocardial  infarction  +  +  +
Arrhythmias  +  +
Previous  cardiac  surgery  +  +  +
Previous  CABG  +
Previous  valvular  surgery  +
Previous  PCI  +
Active  endocarditis  +  +  +
Number  of  diseased  coronary  vessels  +
Type  and  severity  of  valvular  disease (stenosis/regurgitation,  aortic/mitral) +
Haemodynamic  state
Pulmonary  hypertension  +  +
Ejection  fraction  +  +  +  +  +
Critical  preoperative  state  +  +
Cardiogenic  shock  +
Resuscitation  +
Inotropic  agents  +
Intra-aortic  balloon  pump  +
Procedure  +  +  +
Emergency  +  +  +
Surgery  on  thoracic  aorta  +  +  +
Aortic  valve  surgery  +  +
Mitral  valve  surgery  +  +
Aortic  and  mitral  valve  surgery  +  +
Tricuspid  surgery  +
Surgery  for  congenital  heart  disease  +
Rhythmological  surgery  +
Concomitant  CABG  +  +
Concomitant  tricuspid  valve  surgery  +  +
Postinfarct  septal  rupture +
ACEF: age-creatinine-ejection fraction; CABH: coronary artery bypass graft; CCS: Canadian Cardiovascular Society; I: insulin; ES II:
EuroSCORE II; ES-add, additive EuroSCORE; ES-log, logistic EuroSCORE; NYHA: New York Heart Association; PCI: percutaneous coronary
intervention; STS: Society of Thoracic Surgeons.
Modiﬁed from Rosenhek et al. [5].
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Table  2  Baseline  characteristics  of  overall  sample  and  of  survivors  versus  non-survivors.
All  patients  (n  =  314)  Survivors  (n  =  296)  Non-survivors  (n  =  18)  Pa
Age  (years)  73.4  ±  9.7  73.2  ±  9.9  76.8  ±  6.9  0.07
Aged  >  80  years  91  (29)  83  (28)  8  (44)  0.1
Women  129  (41)  122  (41)  7  (39)  0.8
LVEF  (%)  60.7  ±  10  60.5  ±  10  62.4  ±  10  0.5
LVEF  <  30%  5  (2)  5  (2)  0  (0)  1
LVEF  30—50% 41  (13) 39  (13) 2  (11)  1
NYHA  class  III—IV 125 (40) 112  (38) 13  (72) 0.005
Chest  pain 97  (31) 88  (30) 9  (50) 0.4
Syncope  22  (7)  20  (7)  1  (6)  1
Atrial  ﬁbrillation  27  (9)  25  (8)  2  (11)  0.6
Hypertension  204  (65)  190  (64)  14  (78)  0.3
Diabetes  42  (13)  37  (13)  5  (28)  0.07
Body  mass  index  >  30  kg/m2 66  (21)  64  (22)  2  (11)  0.4
Lung  disease  49  (16)  46  (16)  3  (17)  1
Peripheral  vascular  disease  85  (27)  79  (27)  6  (33)  0.6
Cerebrovascular  accident  21  (7)  20  (7)  1  (6)  1
Serum  creatinine  concentration  >  200  mol/L  3  (1)  1  (0.3)  2  (11)  0.09
Creatinine  clearance  <  50  mL/min  35  (11)  28  (9)  7  (39)  0.001
Previous  cardiac  surgery  14  (4)  13  (4)  1  (6)  0.6
Coronary  stenosis  >  50%  125  (40)  113  (38)  12  (67)  0.02
Emergency  surgery  9  (3)  7  (2)  2  (11)  0.08
Charlson-age  co-morbidity  index  3.7  ±  1.4  3.7  ±  1.5  4.3  ±  1.2  0.07
Chest  radiation  therapy  13  (4)  11  (4)  2  (11)  0.2
Mechanical  prosthesis  54  (17)  53  (18)  1  (6)  0.3
Biological  prosthesis  260  (83)  243  (82)  17  (94)  0.3
CABG  69  (22)  62  (21)  7  (39)  0.08
Data are mean ± standard deviation or number (%). CABG: coronary artery bypass graft; LVEF: left ventricular ejection fraction; NYHA:
New York Heart Association.
a Comparisons between survivors and non-survivors.
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We  compared  the  mortality  associated  with  each  score  ver-
sus  CE  at  each  grade  of  risk  deﬁned  by  CE  (Table  5).  The
Table  3  Overall  mortality  predicted  by  the  various
scores.
Score  Percentage
predicted
Predicted/
observed  ratio
EuroSCORE
Additive  6.5  (6.2—6.7)  1.13
Logistic  7.3  (6.8—7.9)  1.27
New  (ES  II)  2.3  (2.1—2.5)  0.40
STS  2.8  (2.6—3.0)  0.49
Ambler  3.3  (3.0—3.5)  0.57
ACEF  2.7  (2.3—2.9)  0.47
Data are mean (95% conﬁdence interval). ACEF: age-creatinine-(range  0.35—1.2  cm2),  the  mean  transvalvular  gradient  was
54  ±  29  mmHg  (range  18—100  mmHg)  and  the  mean  peak
transaortic  ﬂow  was  4.5  ±  1.4  m/s  (range  2.6—6.1  m/s).  The
mean  LVEF  was  60.7  ±  10%  (range  20—78%)  and  18  patients
had  an  LVEF  ≤  40%.  A  bioprosthesis  was  implanted  in  260
(83%)  patients,  a  mechanical  valve  was  implanted  in  54
(17%)  patients  and  at  least  one  CABG  was  performed  in  69
(22%)  patients.  Operative  mortality  was  5.7%  (n  =  18)  and
the  mean  duration  of  index  hospitalization  was  12  ±  6  days.
Mortality  was  10.1%  (7/69)  in  patients  undergoing  AVR  plus
CABG  and  4.5%  (11/245)  in  patients  undergoing  AVR  alone.
Predicting overall mortality
The  overall  predictive  value  of  the  various  models  was
low.  Overall  predicted  mortality  was  generally  underesti-
mated,  ranging  from  a  mean  value  of  2.3%  with  ES  II  to  2.7%
with  ACEF,  2.8%  with  STS  and  3.3%  with  Ambler.  The  pre-
dicted/observed  mortality  ratio  ranged  between  0.40  and
0.57.  On  the  other  hand,  the  6.5%  mortality  predicted  by  ES-
add  and  the  7.3%  mortality  predicted  by  ES-log  were  higher
than  the  observed  mortality  (predicted/observed  mortality
ratios  of  1.13  and  1.27,  respectively)  (Table  3).
The  accuracies  of  the  various  scores  and  CE  were  exam-
ined  by  receiver  operating  characteristic  curves  and  areander  the  curve,  and  were  found  to  be  satisfactory,  ranging
rom  0.66  to  0.77  (Table  4).
isk levelsejection fraction; ES II: EuroSCORE II; STS: Society of Thoracic
Surgeons.
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Table  4  Receiver  operator  characteristic  analysis  of
predicted  operative  mortality.
Score  Area  under  the
curve  (95%  CI)
Clinical  evaluation  0.66  (0.53—0.80)
EuroSCORE
Additive  0.71  (0.59—0.83)
Logistic  0.72  (0.60—0.84)
New  (ES  II) 0.77  (0.65—0.89)
STS  0.73  (0.61—0.86)
Ambler  0.70  (0.59—0.81)
ACEF  0.66  (0.52—0.79)
ACEF: age-creatinine-ejection fraction; CI: conﬁdence interval;
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the  64  patients  classiﬁed  in  grades  III  and  IV  by  CE  and  the
64  patients  at  highest  risk  according  to  each  score  (20%  of
patients  in  each  score).  The  remainder  of  the  patients  were
classiﬁed  as  low  risk.  Besides,  scoring  systems  derived  from
integer  scales  (ES-add,  Ambler  and  ACEF)  resulted  in  many
patients  with  tied  scores,  leading  to  larger  numbers  in  the
group  at  or  above  the  80th  percentile  as  calculated  by  the
score.
The  lowest  high-risk  threshold  was,  by  deﬁnition,  7.0%
for  CE  and  ranged  from  2.6%  for  ACEF  to  10.3%  for  ES-log.
The  highest  predicted  risk  ranged  from  12.0%  for  ES-add  to
31.0%  for  ACEF  (Table  6).  The  mean  predicted  risk  was  4.4%
for  ACEF,  5.2%  for  ES  II,  5.5%  for  STS  and  Ambler,  8.8%  for
ES-add  and  15.1%  for  ES-log.  Only  19  patients  were  included
in  the  high-risk  group  of  all  six  scores  and  20  other  patients
were  included  in  the  high-risk  group  of  ﬁve  scores  (total
n  =  39),  highlighting  the  heterogeneity  of  the  results.  In  this
population,  the  predicted/observed  mortality  ratio  was  con-
sistent,  with  an  overestimated  risk  (1.39)  by  ES-log  and  an
underestimated  risk  by  the  other  scores,  ranging  from  0.30
for  ES  II  to  0.81  for  ES-add.
The  mortality  observed  in  the  high-risk  group  of  each
score  deﬁned  the  positive  predictive  value  of  that  score.  The
positive  predictive  value  for  mortality  in  the  high-risk  groups
was  highest  (17.2%)  for  ES  II  and  decreased  to  14.1%  for  CE
and  STS,  10.9%  for  ES-add  and  ES-log,  10.6%  for  ACEF  and
10.2%  for  Ambler.  The  negative  predictive  value  (or  inclu-
sion  in  the  lowest  group)  was  nearly  identical  (96—97%)  for
all  scores  and  CE,  with  an  observed  mortality  in  the  low-risk
groups  of  2.8—4.4%  (Fig.  2).  The  differences  between  high-
and  low-risk  groups  were  signiﬁcant  for  all  scores  as  well  as
for  CE  (Table  7).  The  Charlson-age  co-morbidity  index  was
not  correlated  with  operative  mortality  (positive  predictive
value  6.2%,  relative  risk  1.1;  P  =  0.84).
Interobserver reproducibility
We  examined  the  interobserver  agreement  with  regard  toES II: EuroSCORE II; STS: Society of Thoracic Surgeons.
istribution  of  patients  varied  widely  among  the  methods
Fig.  1).  CE  classiﬁed  128  patients  (41%)  in  risk  grade  I,  122
39%)  in  grade  II,  42  (13%)  in  grade  III  and  22  (7%)  in  grade  IV.
he  correlation  between  CE  and  the  scores,  albeit  signiﬁcant
P  <  0.05),  was  globally  weak,  with  a  kappa  index  calculated
s  being  between  0.07  and  0.25  when  the  scores  were  tested
n  pairs.  The  highest  kappa  indices  were  obtained  between
S-add  and  ES-log  (0.41;  CI  0.35—0.46),  between  ES  II  and
TS  (0.37;  CI  0.29—0.46)  and  between  STS  and  Ambler  (0.37;
I  0.26—0.43).  The  proportion  of  patients  estimated  to  be
t  low  risk  (<4%:  grade  I)  was  40.7%  for  CE;  for  the  scores
his  ranged  between  12.7%  for  ES-add  and  87%  for  ES  II.  A
isk  classiﬁcation  in  grade  I  (0—3.9%),  whatever  the  method,
as  reliably  predictive  of  survival,  as  the  observed  mortality
anged  between  0%  and  4.9%.  However,  for  grades  II—IV,  the
oncordance  between  CE  and  the  six  scores  was  poor,  as  few
atients  were  classiﬁed  in  grade  III  and  only  1—5  patients
ere  classiﬁed  in  grade  IV  using  STS,  ES  II,  Ambler  and  ACEF.
igh-risk patientsn  this  analysis,  we  compared  the  performance  of  CE  versus
ach  score,  within  groups  deﬁned  as  being  at  high  risk,  i.e.
igure 1. Mortality predicted by clinical evaluation (CE) and
he six scores (see Table 4). ACEF: age-creatinine-ejection frac-
ion; AES: additive EuroSCORE; ES II: EuroSCORE II; LES: logistic
uroSCORE; STS: Society of Thoracic Surgeons.
the  distribution  of  patients  to  the  high-  versus  low-risk
groups  by  CE  grading.  Among  84  patients  who  were  also
evaluated  by  a  surgeon  and  68  who  were  also  evaluated  by
an  anaesthesiologist,  71  (85%)  and  56  (82%),  respectively,
were  assigned  the  same  classiﬁcation  as  they  were  given
initially  by  the  cardiologists.  The  strength  of  agreement  for
the  kappa  coefﬁcient  was  0.51  and  0.40,  respectively.
Figure 2. Observed mortality (%) in high-risk (≥ 80th percentile)
and low-risk groups. ACEF: age-creatinine-ejection fraction; AES:
additive EuroSCORE; CE: clinical evaluation; ES II: EuroSCORE II;
LES: logistic EuroSCORE; STS: Society of Thoracic Surgeons.
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Table  5 Observed  operative  deaths  according  to  the  risk  level  by  clinical  evaluation  and  the  six  scores.
CE  EuroSCORE  STS  Ambler  ACEF
Additive  Logistic  New  (ES  II)
Grade
I  4/128  (3.1) 0/40  (0)  2/93  (2.2)  9/275  (3.3)  9/247  (3.6)  6/196  (3.1)  14/285  (4.9)
II  5/122  (4.1) 3/98  (3.1)  1/77  (1.3)  8/29  (27.6)  5/55  (9.1)  8/97  (8.2)  4/23  (17.4)
III  7/42  (16.7)  11/155  (7.1)  8/72  (11.1)  1/6  (16.7)  4/11  (36.4)  3/16  (18.7)  0/1  (0)
IV  2/22  (9.1) 4/21  (19.1) 7/72  (9.7) 0/4  (0) 0/1  (0)  1/5  (20.0)  0/5  (0)
Kappa  coefﬁcient —  0.13  (0.08—0.18) 0.18  (0.12—0.24) 0.1  (0.05—0.15) 0.14  (0.08—0.20) 0.25  (0.18—0.33)  0.07  (0.02—0.04)
Data are number of deaths/number of patients (% of deaths). ACEF: age-creatinine-ejection fraction; CE: clinical evaluation; ES II: EuroSCORE II; STS: Society of Thoracic Surgeons.
Predicted mortality: Grade I: 0—3.9%; grade II: 4—6.9%; grade III: 7—9.9%; grade IV: ≥10%.
The agreement between CE and each score is indicated by the kappa coefﬁcient (95% conﬁdence interval).
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Table  6  Mean  predicted  and  observed  mortality  in  high-risk  group.
Score  Mortality  (%)  Predicted/observed
Predicted Observed
EuroSCORE
Additive  8.8  (8.0—12.0) 10.9 0.81
Logistic  15.1  (10.3—30.6) 10.9 1.39
New  (ES  II) 5.2  (3.2—12.8) 17.2 0.30
STS  5.5  (4.1—12.2)  14.1  0.39
Ambler  5.5  (4.1—14.3)  10.2  0.54
ACEF  4.4  (2.6—31.0)  10.6  0.42
Clinical  evaluation  ≥7.0  14.1  Not  applicable
Data are mean (range) and ratio of predicted/observed. ACEF: age-creatinine-ejection fraction; ES II: EuroSCORE II; STS: Society of
Thoracic Surgeons.
Table  7 Observed  mortality  in  high-risk  and  low-risk  groups.
CE  EuroSCORE  STS  Ambler  ACEF
Additive  Logistic  ES  II
Observed
mortality
Risk  group
High  9/64  (14.1)  12/110  (10.9)  7/64  (10.9)  11/64  (17.2)  9/64  (14.1)  12/118  (10.2)  10/94  (10.6)
Low  9/250  (3.6)  6/204  (2.9)  11/250  (4.4)  7/250  (2.8)  9/250  (3.6)  6/196  (3.1)  8/220  (3.6)
Predictive
valuea
Positive  0.14  0.11  0.11  0.17  0.14  0.1  0.11
Negative  0.96  0.97  0.96  0.97  0.96  0.97  0.96
Relative  risk
(95%  CI)
3.9 (1.6—9.4)  3.7  (1.4—9.6)  2.5  (1—6.1)  6.1  (2.5—15.2)  3.9  (1.6—9.4)  3.3  (1.3—8.6)  2.9  (1.2—7.2)
P  0.004  0.004  0.04  0.0001  0.004  0.009  0.01
Risk group values are number of deaths/number of patients (% deaths). ACEF: age-creatinine-ejection fraction; CE: clinical evaluation;
CI: conﬁdence interval; ES II: EuroSCORE II; STS: Society of Thoracic Surgeons.
a The positive and negative predictive values were calculated as a function of the number of deaths in the high-risk group.
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aeath analysis
he  risk  proﬁle  of  patients  who  died  was  more  severe  than
hat  of  survivors  (Table  2).  However,  the  difference  was
igniﬁcant  by  single  variable  analysis  only  for  New  York
eart  Association  functional  classes  III  and  IV,  an  estimated
reatinine  clearance  (using  Modiﬁcation  of  Diet  in  Renal
isease)  <  50  mL/min  and  the  presence  of  signiﬁcant  coro-
ary  lesions.  For  each  score,  the  mean  predicted  mortality
as  higher  for  non-survivors  than  for  survivors:  8%  vs.  6.4%
or  ES-add;  11.1%  vs.  7%  for  ES-log;  3.9%  vs.  2.2%  for  ES
I;  4.3%  vs.  2.7%  for  STS;  5%  vs.  3.2%  for  Ambler;  and  3%
s.  2.6%  for  ACEF.  However,  because  of  the  greater  num-
er  of  patients  classiﬁed  as  being  at  low  risk,  the  absolute
umber  of  patients  who  died  in  that  group  approached
he  number  of  patients  who  died  in  the  high-risk  groups
f  all  scores.  Only  three  non-survivors  were  included  in
he  high-risk  group  of  all  scores,  while  two  were  included
n  none.
s
u
aiscussion
his  is,  to  the  best  of  our  knowledge,  the  ﬁrst  comparison  of
he  respective  performance  of  bedside  CE  in  ‘‘real-life’’  cir-
umstances  versus  the  risk  scores  used  most  often  in  valve
urgery.  A  simple  bedside  CE  appears  as  reliable  as  the  var-
ous  established  scores  for  predicting  the  operative  risk  in
atients  undergoing  surgical  AVR.  When  the  estimated  risk
as  <  7%  (grades  I—II),  the  observed  mortality  was  3.6;  when
t  was  ≥  7%  (grades  III—IV),  the  observed  mortality  was  14.1%
i.e.  a  relative  risk  ratio  of  approximately  4).  The  predic-
ive  value  of  CE  was  similar  to  that  of  the  best  performing
cores,  although,  in  our  sample  population,  ES  II  was  the
ost  discriminate.  The  interobserver  reproducibility  of  CE,
s  assessed  by  cardiologists,  cardiac  surgeons  and  anaesthe-
iologists,  was  satisfactory  (82—85%).
Estimation  of  operative  risk  has  been  sharpened  by  the
se  of  validated  scores,  which  confer  better  standardization
nd  greater  objectivity.  The  development  of  TAVI  techniques
t
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eOperative  risk  in  severe  aortic  valve  stenosis  
has  heightened  interest  in  identifying  high-risk  patients.  All
professional  practice  guidelines  have  placed  clinical  judge-
ment  and  the  combined  use  of  scores  —  usually  speciﬁc
cardiological  scores  —  at  the  core  of  the  patient  selection
process  [2,5].  Despite  the  important  contribution  they  make
to  the  decision-making  process,  the  validity  of  the  main
scores  has  been  challenged  for  several  reasons,  including
differences  in  the  choice  of  variables  used,  their  deﬁni-
tions  and  respective  weights,  their  temporal  variations  [13],
their  derivation  from  patients  who  underwent  mostly  CABG
and  their  non-speciﬁc  design  for  valve  disease.  Some  fac-
tors,  poorly  known  or  too  infrequent  to  modify  the  overall
discriminating  power  of  the  scores  (e.g.  chest  radiation
therapy,  porcelain  aorta,  frail  state,  undernutrition,  mor-
bid  obesity,  cancer  and  blood  or  liver  disease),  can  be
important  at  an  individual  level  [4,5].  In  absence  of  major
co-morbidity,  the  overall  negative  predictive  value  of  scores
is  satisfactory,  although  their  positive  predictive  value  is
low.  The  strength  of  clinical  judgement  is  its  ability  to  incor-
porate  important  individual  variables  that  are  not  included
in  the  scores.
In  our  sample,  a  comparative  analysis  found  major  dif-
ferences  between  scores  in  the  absolute  estimation  of  risk;
this  was  overestimated  by  ES-add  and  ES-log  especially  and
underestimated  by  the  other  scores,  as  observed  in  other
studies  [13—16].  Few  patients  had  a  predicted  risk  >  10%  by
STS,  ES  II  and  Ambler,  in  part  as  a  direct  consequence  of
the  advent  of  TAVI,  which  gathered  the  most  seriously  ill
patients.  The  only  risk  group  that  was  reliably  classiﬁed
by  all  scores  was  that  below  4%.  The  lack  of  agreement
among  scores  in  the  classiﬁcation  of  high-risk  patients  has
been  widely  emphasized  by  a  majority  of  investigators
[5,6,13—18],  illustrating  the  limitations  of  calibration  of
most  scores.  This  being  the  case,  an  analysis  that  selects  the
patients  at  highest  risk  (discrimination)  within  each  score
seems  the  most  appropriate.  According  to  Van  Gameren
et  al.  [16],  ‘‘Discrimination  captures  the  model’s  ability
to  distinguish  between  patients  who  will  suffer  from  an
event  and  those  that  will  not.  Calibration  reﬂects  the  rela-
tion  between  the  observed  number  of  events  and  predicted
probability  of  events. .  .  Calibration  is  less  crucial  than  dis-
crimination  in  the  evaluation  process  because  models  can
be  recalibrated’’.  This  approach,  adopted  by  other  authors
(Dewey  et  al.  in  particular  [14]),  enables  the  risk  stratiﬁca-
tion  power  to  be  examined,  regardless  of  the  concordance
in  the  absolute  values  of  observed  and  estimated  risks.  The
most  accurate  predictive  value  of  death  by  a  classiﬁca-
tion  ≥  80th  risk  percentile  was  obtained  with  ES  II,  followed
by  CE  and  STS  equally  (Tables  6  and  7).  The  performance  of
the  other  scores  was  non-signiﬁcantly  lower.
Operative  risk  is  related  to  the  patient’s  cardiovascu-
lar  status,  the  presence  of  concomitant  disorders  and  the
surgical  procedure.  In  the  case  of  AVR,  the  contribution
by  the  surgical  procedure  seems  minimal,  as  the  mortal-
ity  observed  in  otherwise  healthy  and  low-risk  patients  is
low.  It  is,  however,  not  0%,  due  to  the  inevitable  risk  repre-
sented  by  the  ‘‘surgical  hazard’’.  The  imperfect  correlation
with  observed  mortality  that  exists  in  the  other  risk  groups
suggests  that  the  scores  can  be  improved.  Much  has  been
written,  in  recent  years,  about  the  frailty  factors  that  are
not  included  in  the  scores,  related,  to  a  large  extent,  to
age  and  manifestations  of  general  physiological  decay  and
m
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o  lower  resistance  to  surgical  or  non-surgical  interventions
19—23]. In  cardiac  surgery  —  and  aortic  stenosis  in  partic-
lar  —  several  studies  have  found  the  speciﬁc  evaluation  of
railty  valuable  and  have  proposed  speciﬁc  and  more  objec-
ive  geriatric  scores  than  an  empirical  list  of  non-quantiﬁed
ariables  (eyeball  test)  [19—24]. An  independent  correla-
ion  has  been  found  between  frailty  scores  and  mortality
t  1  month  —or  even  1  year  —after  cardiac  surgery  [22,23].
he  Charlson-age  co-morbidity  index  is  non-speciﬁc  and  is
ostly  valuable  prognostically  in  the  long  term  [24].
tudy limitations
he  main  limitation  of  our  study  may  be  related  to  the
ubjectivity  of  CE.  Besides  the  fact  that  it  is  the  topic  of
he  study,  this  apparent  subjectivity  is  limited  by  medi-
al  knowledge  and  is  inherent  to  the  practice  of  medicine
nd  ‘‘clinical  judgement’’.  It  can  be  found  in  many  other
reas,  such  as  in  the  estimation  of  functional  status  by  the
ew  York  Heart  Association  classiﬁcation  [25]  or  in  diagnos-
ic  tests  such  as  the  echocardiographical  measurement  of
VEF  [26], which  both  contribute  greatly  to  many  important
ecisions.  Nevertheless,  interobserver  agreement  conﬁrmed
he  reproducibility  of  clinical  judgement  by  an  experienced
eam.  Secondly,  few  patients  in  our  series  had  a  predicted
isk  >  10%  by  STS,  ES  II  and  Ambler  scores.  This  was  mostly
ue  to  the  fact  that  the  most  severe  patients  were  prefer-
ntially  referred  to  TAVI.  From  this  standpoint,  our  data  do
ot  allow  assessment  of  the  surgical  outcome  of  the  patients
elonging  to  the  highest  classes  of  risk  in  comparison  with
AVI  but  remain  applicable  to  the  present  surgical  popula-
ion.
Another  limitation  pertains  to  the  quantiﬁcation  of  CE.
 continuous  scale  of  risk  in  percentages  might  have  facili-
ated  comparisons.  However,  a  semiquantitative  attribution
f  risk  levels  seemed  closer  to  usual  clinical  practice.  Fur-
hermore,  although  used  by  others  [27], the  thresholds  of
igh  risk  might  seem  arbitrary  and  poorly  adapted  to  some
cores.  As  mentioned  earlier,  this  limitation  is  mostly  due
o  the  scores  themselves  and  can  be  overcome  in  part  by  a
tudy  of  patients  at  high  risk  within  each  score.
Finally,  this  is  a  study  in  a  single  experienced  centre
nvolving  a  relatively  limited  number  of  patients  and  with  a
ide  95%  CI  of  the  relative  risk,  which  can  be  considered  as  a
reliminary  work;  so  the  results  might  vary  among  centres.
evertheless,  given  the  ﬁrst  results  and  the  discrepancies
etween  scores,  it  seems  very  unlikely  that  increasing  the
umber  of  patients  would  demonstrate  the  superiority  of  all
hose  scores  over  CE.
onclusion
E  and  existing  scores  perform  better  in  the  estimation  of
ow  rather  than  high  operative  risk  of  AVR.  In  our  study,  the
ost  accurate  prediction  of  death  was  by  ES  II,  followed
y  CE  and  STS  equally.  So,  a  simple  pragmatic  CE  by  an
xperienced  heart  valve  team  seemed  to  give  a  reliable  esti-
ation  of  operative  risk  of  AVR,  similar  to  that  yielded  by
he  main  scores,  some  of  the  deﬁciencies  of  which  it  might
erhaps  rectify.  A  large-scale  validation  of  more  comprehen-
ive  risk  stratiﬁcation  tools,  particularly  the  frailty  of  elderly
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atients  as  well  as  surgical  risk  factors  thus  far  neglected,
eems  warranted.
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